10 CFOs in Pharmaceuticals
Chief financial officer is the current title for everyone here, at companies from AbbVie, AstraZeneca and Alexion to Catalyst, Collegium and ANI Pharmaceuticals, with two at Pfizer Ltd and Sanofi India Limited. Their other titles cover tax and treasury, R&D finance, business development finance, mature products and commercial finance, which suits a drugmaker planning a launch, an R&D budget, a deal or the years after exclusivity ends.
Professionals to explore
Aaron Rosenberg, CFA
LinkedInExperience: Former Chief Financial Officer · BeOne Medicines
In 2024, Aaron Rosenberg, CFA became Chief Financial Officer at BeOne Medicines, after Senior Vice President Finance, Corporate Treasurer at Merck (2021–2024). Earlier Merck titles include Senior Vice President, Corporate Strategy and Planning (2019–2021), Vice President Finance, Merck Animal Health CFO (2015–2018) and Associate Vice President Finance, Global Human Health (2013–2015).
Is this you? Claim your profile and get paid for calls.
Amit Agarwal
LinkedInExperience: Former Executive Director Finance & Chief Financial Officer, Pfizer Ltd · Pfizer
Since 2024, Amit Agarwal has been Executive Director Finance & Chief Financial Officer, Pfizer Ltd, after General Manager Finance - Sales & Customer Development at Unilever (2022–2024). Other Unilever titles were General Manager - Internal Audit (2020–2022) and Finance Controller - Global Business Services (2016–2020), so Amit can compare pharmaceutical finance with the sales finance and audit roles held at Unilever.
Is this you? Claim your profile and get paid for calls.
Colleen Tupper
LinkedInExperience: EVP & Chief Financial Officer · Collegium Pharmaceutical, Inc.
For commercial finance and integration questions, Colleen Tupper is a fit: EVP & Chief Financial Officer at Collegium Pharmaceutical, Inc. since 2021, after Senior Vice President & CFO, U.S. Business Unit at Takeda (2019–2021). At Shire, Colleen was Vice President, US Commercial Finance (2016–2019), Vice President, Finance Integration Lead (2016) and Vice President, Head of Finance Global Neuroscience & Ophthalmics (2015–2016).
Is this you? Claim your profile and get paid for calls.
Katharina Russo
LinkedInExperience: Chief Financial Officer · Pharmacosmos Therapeutics Inc.
Pharmacosmos Therapeutics Inc., described as the company's US distribution arm founded in 2019, has had Katharina Russo as Chief Financial Officer since 2023. At Novartis, Katharina was Vice President Finance (2022–2023), Head of Finance Cardio-Renal-Metabolic Business Unit (2017–2022), Executive Director, Business Development Finance (2015–2017) and Executive Director, Primary Care and Mature Products Business Unit (2012–2015).
Is this you? Claim your profile and get paid for calls.
Michael Kalb
LinkedInExperience: EVP & Chief Financial Officer · Catalyst Pharmaceuticals, Inc.
Michael Kalb has held five CFO titles: EVP & Chief Financial Officer at Catalyst Pharmaceuticals, Inc. (since 2024), Chief Financial Officer at Impel Pharmaceuticals (2023), EVP & Chief Financial Officer at CinCor Pharma, Inc. (2022–2023), SVP & Chief Financial Officer at Amarin Corporation (2016–2022) and Chief Financial Officer and Chief Accounting Officer, Group V.P. at Taro Pharmaceuticals (2009–2016).
Is this you? Claim your profile and get paid for calls.
Priscila Plaza
LinkedInExperience: Chief Financial Officer · AstraZeneca
Priscila Plaza has been Chief Financial Officer at AstraZeneca since 2022 and was Executive Controller there (2020–2022). Earlier, Priscila was FP&A & Commercial Finance Executive Director Transition Leader at GE HealthCare (2015–2020) and CFO, Wind Latin America at GE (2010–2015), which suits questions on controllership and commercial finance.
Is this you? Claim your profile and get paid for calls.
Scott Reents
LinkedInExperience: Executive Vice President, Chief Financial Officer · AbbVie
AbbVie's Executive Vice President, Chief Financial Officer since 2022, Scott Reents is responsible for AbbVie's global financial and business technology operations, and also held Senior Vice President, Chief Financial Officer in 2022. Scott was Vice President, Tax and Treasury (2019–2022) and Vice President, Tax (2013–2019) at AbbVie, and served as Corporate Treasurer, a fit for tax and treasury questions.
Is this you? Claim your profile and get paid for calls.
Sean Christie
LinkedInExperience: Chief Financial Officer · Alexion Pharmaceuticals, Inc.
Chief Financial Officer at Alexion Pharmaceuticals, Inc. since 2021, Sean Christie was VP Finance R&D at AstraZeneca (2018–2021). Other AstraZeneca titles were CFO China & Hong Kong (2015–2018), Area Finance Director - Middle East & Africa (2012–2015) and CFO Gulf States (2011–2012), so Sean can speak to R&D budgets and to finance in several regions.
Is this you? Claim your profile and get paid for calls.
Stephen Carey
LinkedInExperience: Senior Vice President, Finance and Chief Financial Officer · ANI Pharmaceuticals, Inc.
At ANI Pharmaceuticals, Inc., Stephen Carey has been Senior Vice President, Finance and Chief Financial Officer since 2016. Par Health titles were Senior Vice President, Corporate Controller and Principal Accounting Officer (2015), Senior Vice President, Corporate Controller (2011–2014) and Vice President and Controller (2007–2011), and Stephen was Director of Finance, EUCAN at Merck (2005–2007).
Is this you? Claim your profile and get paid for calls.
Vaibhav Karandikar
LinkedInExperience: Chief Financial Officer · Sanofi India Limited
Vaibhav Karandikar's titles are all at Sanofi India: Chief Financial Officer since 2020, after Sr. Director Finance (2016–2020), Director Accounting & Taxation (2014–2016), Director Accounting & Direct Tax (2012–2014) and Associate Director Accounting & Direct tax (2007–2012). That accounting and tax path suits questions on statutory reporting and tax at Sanofi India.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For launch and commercial finance, Colleen Tupper and Katharina Russo held US commercial and business unit finance titles at Shire and Novartis; for tax, treasury and capital structure, Scott Reents and Aaron Rosenberg, CFA. Sean Christie is the match for R&D spending, Michael Kalb has held CFO titles at five companies, and Amit Agarwal and Vaibhav Karandikar bring the Pfizer Ltd and Sanofi India Limited view.
Questions to take into the conversation
- 01How far ahead do you plan for loss of exclusivity on a major product, and what changes in the budget first?
- 02How do you decide how much R&D spending to protect when a launch comes in below plan?
- 03What does the finance setup for a launch need in the year before approval?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.